

# Revisiting Short-Chain Fatty Acids and the Microbiota in Colorectal Cancer

Running title: SCFAs and Colorectal Cancer

Marc A Sze<sup>1</sup>, Nicholas A Lesniak<sup>1</sup>, Mack T Ruffin IV<sup>2</sup>, Patrick D. Schloss<sup>1†</sup>

† To whom correspondence should be addressed: [pschloss@umich.edu](mailto:pschloss@umich.edu)

<sup>1</sup> Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109

<sup>2</sup> Department of Family Medicine and Community Medicine, Penn State Hershey Medical Center, Hershey, PA

## Abstract

**Background.** Certain bacterial community members have been shown to increase colon tumorigenesis while other taxa have been associated with normal colons. The some of the taxa associated with normal colons can use fiber to produce short-chain fatty acids which have been shown to inhibit tumor growth in model systems. However, the data supporting the importance of SCFAs in humans is less certain. Here we test the hypothesis that short-chain fatty acid concentration decreases in individuals with colorectal tumors.

**Methods.** We analyzed a cross-sectional (n=490) and pre- and post-treatment (n=67) group for their concentrations of acetate, butyrate, and propionate. Analysis also included tumor classification models using Random Forest, imputed gene relative abundance with PICRUSt, and metagenomic sequencing on a subset (n=85) of the total cross-sectional group.

**Results.** No difference in short-chain fatty acid concentration was found between normal individuals and patients with adenoma or carcinoma (P-value > 0.15). There was no difference in the ability of classification models with or without short-chain fatty acids added to them in predicting adenoma or carcinoma (P-value > 0.05). Using metagenomic sequencing, there was also no difference in genes involved with short-chain fatty acid synthesis (P-value > 0.70).

**Conclusions.** Although our data does not support the hypothesis that short-chain fatty acids decrease in individuals that have colorectal tumors, there may be specific scenarios where short-chain fatty acids may still be beneficial for treatment of colorectal cancer. Alternatively, there may be other metabolites that have not been thoroughly investigated that are more important to human colorectal cancer.

## 22 Introduction

23 Colorectal cancer (CRC) is currently the third leading cancer-related cause of death within the US  
24 (1, 2). The environment has been attributed as an important risk factor for CRC (3). This has lead  
25 to the investigation of how the microbiota may exacerbate or cause tumorigenesis (4–6) and whether  
26 the bacterial community is altered (7, 8). Multiple reports in case/control studies on the microbiota  
27 and CRC have identified taxa commonly associated with the normal colon to be decreased in  
28 patients with carcinoma tumors (9–11). Many of these taxa actively produce short-chain fatty acids  
29 (SCFAs) from fiber that is part of our general diet (12). The most extensively studied of these  
30 SCFAs are acetate, butyrate, and propionate (13). Overall, CRC is a growing health problem and  
31 the microbiota through SCFAs have shown promise as a viable treatment option.

32 Within model systems SCFAs, in particular butyrate, have shown positive results in CRC treatment  
33 (14). In particular, butyrate has been shown to inhibit cancer cell growth in *in vitro* systems (15).  
34 Additionally, supplementation with food sources that bacteria use to create these SCFAs may also  
35 be able to confer beneficial effects. Fiber supplementation in mouse models of CRC caused an  
36 overall reduction in tumor burden while also increasing SCFA concentrations (16). Although these  
37 model systems provide important preliminary evidence towards the ability of SCFAs to reduce and  
38 treat tumors, the studies reporting benefit in humans has been less convincing.

39 There is a lack of evidence on the benefit of increasing SCFA concentrations to protect against  
40 CRC in human populations. The initial case/control studies that investigated SCFA concentrations  
41 in CRC have found that patients with carcinomas had lower concentrations of acetate, butyrate, and  
42 propionate versus patients with adenomas and individuals with normal colons (17). Although this  
43 would argue that increasing SCFA concentrations could be protective against tumorigenesis, fiber  
44 supplementation in randomized controlled trials have consistently failed to protect against tumor  
45 recurrence (18). These findings would argue against the utility of treatments that aim to use SCFAs  
46 to reduce or protect against tumorigenesis. Given the lack of clear evidence in human studies of  
47 the benefit of SCFAs in CRC there is a need for more investigation into this area.

48 Our current study will fill some of the current gaps in the literature that relate to the study of SCFAs

49 and CRC in human populations. Specifically, it will attempt to replicate previous case/control  
50 findings on SCFA concentrations in individuals with and without tumors. Additionally, by increasing  
51 the adenoma tumor cohort it we will be able to identify if the observation of a continuous gradual  
52 reduction in SCFA concentrations occurs as tumor severity increases. It also will build upon these  
53 observations and assess the utility of using SCFAs and Operational Taxonomic Units (OTUs) as a  
54 potential risk stratification tool of colorectal tumors. This study will provide important information  
55 on the replicability of previous findings in humans by extensively studying how SCFAs could be  
56 associated with colorectal tumors.

57 To accomplish this task we will directly measure the concentration of acetate, butyrate, and  
58 propionate within fecal samples for two different groups. The first group will be at a cross sectional  
59 point in time while the second group will be before (pre-) and after (post-)treatment. Additionally,  
60 we also will assess whether adding SCFA concentrations to OTU data improves the classification  
61 of adenoma or carcinoma, use PICRUST and metagenomic sequencing to assess the genes  
62 involved in SCFA synthesis, and analyze how well 16S rRNA gene sequencing can predict SCFA  
63 concentrations. This extensive investigation will provide additional information as to whether the  
64 taxa that are decreased in carcinoma use SCFAs to help protect against tumorigenesis.

## Results

**Decreased SCFA concentrations are not associated with tumors.** We used frozen fecal samples from 490 individuals and HPLC to measure acetate, butyrate, and propionate concentrations at a cross-sectional point in time. There was no difference between individuals with normal colons (n=172) and patients with either an adenoma (n=198) or carcinoma (n=120) for any of the SCFAs measured after multiple comparison correction (P-value > 0.15) [Figure 1A - 1C]. We next measured the concentration of SCFAs in 67 patients with an adenoma (n=41) or carcinoma (n=26) in which we had pre- and post-treatment fecal samples. Although there was a general trend for increasing acetate, butyrate, and propionate concentrations after treatment for tumors, there was no significant difference pre- and post-treatment for patients with adenoma (P-value > 0.20) or carcinoma (P-value > 0.80) [Figure 1D - 1F]. Even though there was no change in SCFA concentrations between individuals with normal colons and those with tumors, this information could still be important to help classify disease.

**Random Forest models with SCFA concentrations do not classify tumors better.** Using the Random Forest algorithm we built models to classify normal versus adenoma and normal versus carcinoma with OTUs or OTUs and SCFA concentrations. For both adenoma and carcinoma models, there was no difference between the median AUC of models with or without SCFA concentrations (P-value > 0.05) [Figure 2]. Although including SCFA concentrations did not add extra information for classification of disease using Random Forest models, it is possible that the genes for enzymes involved in SCFA synthesis may change due to disease status; where a smaller number of microbes are responsible for the observed SCFA concentrations.

**Changes in genes for enzymes involved in SCFA synthesis are not associated with tumors.** Using a list of specific genes that are important for the synthesis of SCFAs [Table S1], we looked for differences in gene abundance based on individuals having normal colons, adenomas, or carcinomas. First, using imputed gene relative abundance based on 16S rRNA gene sequencing we found no difference in any of the genes involved with acetate, butyrate, or propionate synthesis (P-value > 0.90) [Table S2]. This similarity between groups is highlighted by visualizing genes important in butyrate synthesis [Figure 3A]. Next, we took a subset of these 490 fecal samples

(n=85) and performed metagenomic sequencing to confirm these results. Like the imputed gene results, metagenomic analysis found that there was no difference in any of the genes involved in SCFA synthesis between individuals with normal colons (n=29) and patients with adenoma (n=28) or carcinoma (n=28) (P-value > 0.70) [Table S3]. This lack of difference is highlighted when we visualize the results for butyrate kinase [Figure 3B]. These observations provide evidence that the gene content does not change due to tumors. Although these results suggest that SCFA concentrations do not change due to tumor, there may be some errors present within our results that may account for the lack of associations.

**Expected taxa are associated with higher SCFA concentrations regardless of tumor status.**

Using OTU data we built Random Forest models to classify higher than median and lower than median SCFA concentrations. Overall, OTU data had a reasonable ability to classify high and low SCFA concentrations [Figure S1A]. However, these models tended to be overfit, suggesting that rarer taxa may be important for this classification [Figure S1A]. The most important OTUs to these models (assessed with mean decrease in accuracy (MDA)) were to taxa that are normally associated with SCFA production [Figure S1B]. These results highlight that there are no immediately apparent errors in our data because SCFA concentrations are associated with taxa known to produce acetate, butyrate, and propionate. Additionally, OTUs associated with these taxa are the most important to models that can classify high and low SCFA concentrations. Overall, our results do not support the hypothesis that lower SCFA concentrations are associated with colorectal cancer.

## Discussion

The observations from this study do not support the hypothesis that SCFA concentrations are lower in individuals with tumors. Whether we directly measured the SCFA concentration or investigate genes associated with their production no difference could be identified [Figure 1 & 3]. Further, no benefit could be found in using the concentrations to help classify individuals with and without tumors [Figure 2]. These observations are in stark contrast to some of the previous literature.

Much of the previous literature on SCFA benefit to human colorectal cancer has been illustrated in model systems (14). Many SCFAs are produced through the breakdown of fiber (12). A recent study in mice found that fiber supplementation increased SCFA concentration and decreased tumor burden (16). Additionally, SCFAs such as butyrate have been found to inhibit tumor growth in *in vitro* experiments (15). Yet, observations in humans has been mixed. Previous case/control studies have suggested that SCFAs are lower in individuals with carcinoma tumors (17). However, individual studies and meta-analysis on fiber supplementation to prevent tumor recurrence have found no benefit (18, 19). Our results align with what has been reported in randomized-controlled trials that SCFAs do not protect against all types of colorectal tumors. It is possible though that there are specific instances where SCFAs may be beneficial.

One limitation of ours and others research into the effect of SCFAs in colorectal cancer has been that all tumors are treated as the same type. However, there are known differences in the types of mutations that occur (20) and treating all tumors as equal may actually hide any benefit that could be found in specific subsets of individuals. Similar to the idea of specific immunotherapy for specific tumors (21), SCFAs may have beneficial effects for specific types of colorectal cancers. Future research will need to test if this is a valid hypothesis. Although there are limitations with the current research on SCFAs and colorectal tumors, evidence is building that these specific metabolites may not be protective. Yet, taxa that are associated with SCFA production are consistently higher in normal colons than those with carcinomas (7, 8, 22).

The potential protection against colorectal cancers may not be from SCFAs even though taxa associated with their production are higher in individuals with normal colons versus patients

with carcinomas (7, 8, 22). Protection could be via a different pathway and other metabolites that have not been extensively studied. Alternatively, protection may not occur via a metabolite but instead occur through niche exclusion of mouth-associated microbes (e.g. *Fusobacterium*, *Porphyromonas*, *Parvimonas*, *Peptostreptococcus* (9, 10)). The idea of niche exclusion is similar to how the community protects against *Clostridium difficile* infection with chronic inflammation replacing the role of antibiotics. Although we did not find lower concentrations of SCFAs associated with colorectal tumors, we think that there are many exciting new avenues to explore because of these observations.



## Conclusions

Our observations found no difference in SCFA concentration, their utility as a classification tool, and for genes for enzymes involved in SCFA synthesis between individuals with normal colons and patients with either adenoma or carcinoma tumors. Although these results are different than other reports in the literature, they do align with the randomized controlled trials that have tested fiber use in preventing colorectal tumor recurrence. Overall, these results suggest that the SCFAs produced by resident microbes do not protect against tumor. By focusing on other types of metabolites, the identification of more promising therapeutic options for use in treating colorectal cancer may be found.

## Materials and Methods

**Study design and sampling.** The overall protocol has been described in detail previously (23, 24). In brief, this study used fecal samples obtained at either a single cross-sectional time point (n=490) or from before (pre-) and after (post-) treatment for their tumor (n=67). For patients undergoing treatment for their tumor the length of time between their initial and follow up sample ranged from 188 - 546 days. Our use of treatment has been previously defined as encompassing removal of a tumor with or without chemotherapy and radiation (23). Diagnosis of tumor was made by colonoscopic examination and histopathological review of biopsies obtained (23, 24). The University of Michigan Institutional Review Board approved the study and informed consent was obtained from all participants in accordance to the guidelines set out by the Helsinki Declaration.

**Measuring specific SCFAs.** Our protocol for the measurement of acetate, butyrate, and propionate followed a previously published protocol (25). The following changes to this protocol included the use of frozen fecal samples suspended in 1ml of PBS instead of fecal suspensions in DNA Genotek OmniGut tubes, and the use of the actual weight of fecal samples instead of the average weight for SCFA concentration normalizations. These changes did not affect the overall median concentrations of these SCFAs between the two studies (see Table 1 (25) and Figure 1 in this report).

**16s rRNA gene sequencing.** The workflow and processing have been described previously (23, 26, 27). The major differences from these previous reports include: the use of version 1.39.5 of the mothur software package and clustering Operational Taxonomic Units (OTUs) at 97% similarity used the OptClust algorithm (28).

**Generating imputed metagenomes.** The use of PICRUSt version 1.1.2 with the recommended standard operating protocol (29) was used. Briefly, the mothur shared file and metadata was converted into a biom formatted table using the biom convert function, the subsequent biom file was processed with the normalize\_by\_copy\_number.py function, and subsequent imputed metagenomes created using the predict\_metagenomes.py function.

**Obtaining OPFs from metagenomes.** A subset of the cross-sectional group (n=490) containing a total of 85 individuals (normal n=29 normal, adenoma n=28, and carcinoma n=28) was shotgun

sequenced on an Illumina HiSeq using 125 bp paired end reads and a previously described method (30). Briefly, the sequences were quality filtered and sequences aligning to the human genome were removed prior to contig assembly with MEGAHIT (31). Open Reading Frames (ORFs) were identified using Prodigal (32), counts generated using Diamond (33), subsequent clustering into Operational Protein Families (OPFs) used mmseq2 (34), and OPF alignment used the KEGG database (35).

**Pulling genes involved with SCFA synthesis.** Specific genes located near the end of the pathways involved in the synthesis of acetate, butyrate, and propionate were analyzed for any differences between individuals with normal colons and those with tumors. These genes were based on pathways from KEGG as well as previous research (35, 36) and a list can be found in the supplemental material [Table S1].

**Random Forest Models.** The model was first trained on 80% of the data and then tested on the held out 20% (80/20 split) using the Random Forest algorithm for both classification and regression models (37). This was repeated on 100 different 80/20 splits of the data to generate a reasonable range for the AUC of the model. The reported AUCs, unless otherwise specified, are for the test sets. Classification models were built to group normal versus adenoma and normal versus carcinoma or high versus low SCFA concentrations.

**Statistical analysis workflow.** All analysis was performed using the statistical language R (38). Generally, differences between the different disease groups used a Kruskal-Wallis rank sum test with a Dunn's post-hoc test. Where appropriate Benjamini-Hochberg was used to correct for multiple comparisons (39). First, we assessed differences in SCFA concentrations measured by HPLC between individuals with normal colons and patients with tumors (adenoma or carcinoma). We then analyzed whether SCFA concentrations changed in patients with an adenoma or carcinoma pre-versus post-treatment. Next, we assessed whether OTUs alone or OTUs and SCFAs were better able to classify individuals with and without tumor using Random Forest models. Next, the imputed gene counts of important mediators of SCFA creation were tested. Finally, the counts generated for OPFs that matched important genes involved with SCFA creation were analyzed. Finally, models to classify high or low SCFA concentration based on 16S rRNA gene sequencing data were created

211 using the Random Forest algorithm.

## Acknowledgements

The authors thank the Great Lakes-New England Early Detection Research Network for providing the fecal samples that were used in this study. We would also like to thank Kwi Kim and Thomas M Schmidt for their help in running the short-chain fatty acid analysis on the High-Performance Liquid Chromatography machine at the University of Michigan. Salary support for Marc A. Sze came from the Canadian Institute of Health Research and NIH grant UL1TR002240. Salary support for Patrick D. Schloss came from NIH grants P30DK034933 and 1R01CA215574.

## References

1. **Haggard F, Boushey R.** 2009. Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. *Clinics in Colon and Rectal Surgery* **22**:191–197. doi:10.1055/s-0029-1242458.
2. **Siegel RL, Miller KD, Jemal A.** 2016. Cancer statistics, 2016. *CA: A Cancer Journal for Clinicians* **66**:7–30. doi:10.3322/caac.21332.
3. **Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K.** 2000. Environmental and heritable factors in the causation of cancer analyses of cohorts of twins from sweden, denmark, and finland. *New England Journal of Medicine* **343**:78–85. doi:10.1056/nejm200007133430201.
4. **Zackular JP, Baxter NT, Iverson KD, Sadler WD, Petrosino JF, Chen GY, Schloss PD.** 2013. The gut microbiome modulates colon tumorigenesis. *mBio* **4**:e00692–13–e00692–13. doi:10.1128/mbio.00692-13.
5. **Baxter NT, Zackular JP, Chen GY, Schloss PD.** 2014. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. *Microbiome* **2**:20. doi:10.1186/2049-2618-2-20.
6. **Zackular JP, Baxter NT, Chen GY, Schloss PD.** 2015. Manipulation of the gut microbiota reveals role in colon tumorigenesis. *mSphere* **1**:e00001–15. doi:10.1128/msphere.00001-15.
7. **Shah MS, DeSantis TZ, Weinmaier T, McMurdie PJ, Cope JL, Altrichter A, Yamal J-M, Hollister EB.** 2017. Leveraging sequence-based faecal microbial community survey data to identify a composite biomarker for colorectal cancer. *Gut* **67**:882–891. doi:10.1136/gutjnl-2016-313189.
8. **Sze MA, Schloss PD.** 2018. Leveraging existing 16S rRNA gene surveys to identify reproducible biomarkers in individuals with colorectal tumors. doi:10.1101/285486.
9. **Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Bohm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Nhieu JTV, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, Knebel**

- Doeberitz M von, Sobhani I, Bork P.** 2014. Potential of fecal microbiota for early-stage detection of colorectal cancer. *Molecular Systems Biology* **10**:766–766. doi:10.15252/msb.20145645.
10. **Baxter NT, Ruffin MT, Rogers MAM, Schloss PD.** 2016. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine* **8**. doi:10.1186/s13073-016-0290-3.
11. **Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Taberero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M.** 2011. Genomic analysis identifies association of fusobacterium with colorectal carcinoma. *Genome Research* **22**:292–298. doi:10.1101/gr.126573.111.
12. **Holscher HD.** 2017. Dietary fiber and prebiotics and the gastrointestinal microbiota. *Gut Microbes* **8**:172–184. doi:10.1080/19490976.2017.1290756.
13. **Louis P, Flint HJ.** 2016. Formation of propionate and butyrate by the human colonic microbiota. *Environmental Microbiology* **19**:29–41. doi:10.1111/1462-2920.13589.
14. **O’Keefe SJD.** 2016. Diet, microorganisms and their metabolites and colon cancer. *Nature Reviews Gastroenterology & Hepatology* **13**:691–706. doi:10.1038/nrgastro.2016.165.
15. **Encarnação JC, Pires AS, Amaral RA, Gonçalves TJ, Laranjo M, Casalta-Lopes JE, Gonçalves AC, Sarmiento-Ribeiro AB, Abrantes AM, Botelho MF.** 2018. Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells. *The Journal of Nutritional Biochemistry* **56**:183–192. doi:10.1016/j.jnutbio.2018.02.018.
16. **Bishehsari F, Engen P, Preite N, Tuncil Y, Naqib A, Shaikh M, Rossi M, Wilber S, Green S, Hamaker B, Khazaie K, Voigt R, Forsyth C, Keshavarzian A.** 2018. Dietary fiber treatment corrects the composition of gut microbiota, promotes SCFA production, and suppresses colon carcinogenesis. *Genes* **9**:102. doi:10.3390/genes9020102.
17. **Ohigashi S, Sudo K, Kobayashi D, Takahashi O, Takahashi T, Asahara T, Nomoto K, Onodera H.** 2013. Changes of the intestinal microbiota, short chain fatty acids, and fecal pH in patients with colorectal cancer. *Digestive Diseases and Sciences* **58**:1717–1726.

doi:10.1007/s10620-012-2526-4.

18. **Yao Y, Suo T, Andersson R, Cao Y, Wang C, Lu J, Chui E.** 2017. Dietary fibre for the prevention of recurrent colorectal adenomas and carcinomas. *Cochrane Database of Systematic Reviews*. doi:10.1002/14651858.cd003430.pub2.

19. **Schatzkin A, Lanza E, Corle D, Lance P, Iber F, Caan B, Shike M, Weissfeld J, Burt R, Cooper MR, Kikendall JW, Cahill J, Freedman L, Marshall J, Schoen RE, Slattery M.** 2000. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. *New England Journal of Medicine* **342**:1149–1155. doi:10.1056/nejm200004203421601.

20. **Fearon ER, Vogelstein B.** 1990. A genetic model for colorectal tumorigenesis. *Cell* **61**:759–767. doi:10.1016/0092-8674(90)90186-i.

21. **Thomas X, Heiblig M.** 2016. The development of agents targeting the BCR-ABL tyrosine kinase as philadelphia chromosome-positive acute lymphoblastic leukemia treatment. *Expert Opinion on Drug Discovery* **11**:1061–1070. doi:10.1080/17460441.2016.1227318.

22. **Sze MA, Baxter NT, Ruffin MT, Rogers MAM, Schloss PD.** 2017. Normalization of the microbiota in patients after treatment for colonic lesions. *Microbiome* **5**. doi:10.1186/s40168-017-0366-3.

23. **Sze MA, Baxter NT, Ruffin MT, Rogers MAM, Schloss PD.** 2017. Normalization of the microbiota in patients after treatment for colonic lesions. *Microbiome* **5**. doi:10.1186/s40168-017-0366-3.

24. **Baxter NT, Ruffin MT, Rogers MAM, Schloss PD.** 2016. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine* **8**. doi:10.1186/s13073-016-0290-3.

25. **Venkataraman A, Sieber JR, Schmidt AW, Waldron C, Theis KR, Schmidt TM.** 2016. Variable responses of human microbiomes to dietary supplementation with resistant starch. *Microbiome* **4**. doi:10.1186/s40168-016-0178-x.

26. **Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Horn DJV, Weber CF.**



295 2009. Introducing mothur: Open-source, platform-independent, community-supported software  
 296 for describing and comparing microbial communities. *Applied and Environmental Microbiology*  
 297 **75**:7537–7541. doi:10.1128/aem.01541-09.

298 27. **Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD**. 2013. Development of a  
 299 dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on  
 300 the MiSeq illumina sequencing platform. *Applied and Environmental Microbiology* **79**:5112–5120.  
 301 doi:10.1128/aem.01043-13.

302 28. **Westcott SL, Schloss PD**. 2017. OptiClust, an improved method for assigning  
 303 amplicon-based sequence data to operational taxonomic units. *mSphere* **2**:e00073–17.  
 304 doi:10.1128/mspheredirect.00073-17.

305 29. **Langille MGI, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC,**  
 306 **Burkepile DE, Thurber RLV, Knight R, Beiko RG, Huttenhower C**. 2013. Predictive functional  
 307 profiling of microbial communities using 16S rRNA marker gene sequences. *Nature Biotechnology*  
 308 **31**:814–821. doi:10.1038/nbt.2676.

309 30. **Hannigan GD, Duhaime MB, Ruffin MT, Koumpouras CC, Schloss PD**. 2017. Diagnostic  
 310 potential & the interactive dynamics of the colorectal cancer virome. doi:10.1101/152868.

311 31. **Li D, Liu C-M, Luo R, Sadakane K, Lam T-W**. 2015. MEGAHIT: An ultra-fast single-node  
 312 solution for large and complex metagenomics assembly via succinct de bruijn graph. *Bioinformatics*  
 313 **31**:1674–1676. doi:10.1093/bioinformatics/btv033.

314 32. **Hyatt D, Chen G-L, LoCascio PF, Land ML, Larimer FW, Hauser LJ**. 2010. Prodigal:  
 315 Prokaryotic gene recognition and translation initiation site identification. *BMC Bioinformatics* **11**:119.  
 316 doi:10.1186/1471-2105-11-119.

317 33. **Buchfink B, Xie C, Huson DH**. 2014. Fast and sensitive protein alignment using DIAMOND.  
 318 *Nature Methods* **12**:59–60. doi:10.1038/nmeth.3176.

319 34. **Steinegger M, Söding J**. 2017. MMseqs2 enables sensitive protein sequence searching for

- 320 the analysis of massive data sets. *Nature Biotechnology*. doi:10.1038/nbt.3988.
- 321 35. **Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M.** 2015. KEGG as a  
322 reference resource for gene and protein annotation. *Nucleic Acids Research* **44**:D457–D462.  
323 doi:10.1093/nar/gkv1070.
- 324 36. **Baxter NT, Zackular JP, Chen GY, Schloss PD.** 2014. Structure of the gut microbiome  
325 following colonization with human feces determines colonic tumor burden. *Microbiome* **2**:20.  
326 doi:10.1186/2049-2618-2-20.
- 327 37. **Liaw A, Wiener M.** 2002. Classification and regression by randomForest. *R News* **2**:18–22.
- 328 38. **R Core Team.** 2017. R: A language and environment for statistical computing. R Foundation  
329 for Statistical Computing, Vienna, Austria.
- 330 39. **Benjamini Y, Hochberg Y.** 1995. Controlling the false discovery rate: A practical and powerful  
331 approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological)*  
332 **57**:289–300.

**Figure 1. Using HPLC no change in SCFA measurements was observed between normal, adenoma, and carcinoma individuals.** Acetate concentrations in fecal samples of individuals with normal colons, adenomas, and carcinomas (A). Butyrate concentrations in fecal samples of individuals with normal colons, adenomas, and carcinomas (B). Propionate concentrations in fecal samples of individuals with normal colons, adenomas, and carcinomas (C). The black links indicate the median SCFA concentration. Acetate concentrations in fecal samples before and after treatment for adenoma (yellow) and carcinoma (red) (D). Butyrate concentrations in fecal samples before and after treatment for adenoma (yellow) and carcinoma (red) (E). Propionate concentrations in fecal samples before and after treatment for adenoma (yellow) and carcinoma (red) (F). The black dots and lines represent the median change in SCFA concentration.

**Figure 2. SCFAs do not improve OTU-based Random Forest models.** Difference between the area under the curve of 100 different 80/20 split OTU-based normal versus adenoma 10-fold CV models with and without SCFAs (A). Difference between the area under the curve of 100 different 80/20 OTU-based normal versus carcinoma 10-fold CV models with and without SCFAs (B). The black line represents the median AUC. The dotted line highlights an AUC of 0.5.

**Figure 3. No change in butyrate producing genes identified between normal, adenoma, and carcinoma individuals.** Imputed gene relative abundance of important butyrate pathway genes using PICRUSt (A). Counts per million (corrected for size and number of contigs in an OPF) for the Butyrate Kinase gene (B). The other genes from the PICRUSt analysis did not align to any of the OPFs in the metagenome analysis.

**Figure S1. OTU-based Random Forest models of SCFA concentrations.** Classification

Random Forest train and tests of 100 different 80/20 OTU-based models with 10-fold CV based on higher or lower than the median SCFA concentration (A). The top 10 OTUs based on mean decrease in accuracy (MDA) for each model, colored by their lowest taxonomic identification (B).

Regression Random Forest train and tests of 100 different 80/20 OTU-based models with 10-fold CV based on correlation to actual SCFA concentration (C). The top 10 OTUs based on mean decrease in accuracy (MDA) for each model, colored by their lowest taxonomic identification (D).